Xiaflex 0.9 MG vials
Ended Awarded
- Contract number
- SPE2DB25FD4XQ
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,454
Award facts
- Contract value 100% obligated
- $16,454.48 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a delivery order award from the Defense Logistics Agency (DLA) on September 10, 2025, for Xiaflex 0.9 mg vials with a ceiling value of $16,454.48. This firm fixed-price delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499.999 billion and valid through November 2026. The award carries no set-aside designation, allowing the vendor to compete on the open market while leveraging its woman-owned small business status. Performance is scheduled for completion by October 1, 2025, with work to be performed at the contractor's location in Park Ridge, Illinois.
Xiaflex, a specialty pharmaceutical product indicated for treating Dupuytren's contracture, represents one of many specialized medications DMS Pharmaceutical Group supplies to the Defense Logistics Agency for distribution to Department of Defense healthcare facilities nationwide. The IDC vehicle under which this delivery order was issued demonstrates the DLA's reliance on DMS Pharmaceutical Group as a critical supplier within the federal pharmaceutical supply chain, encompassing a comprehensive portfolio of branded and generic prescription drugs, biologics, and medical consumables across diverse therapeutic categories. The company's consistent success in securing federal pharmaceutical contracts without specific set-aside designations underscores its competitive positioning in the government procurement marketplace.
Quick answers
Who was awarded contract SPE2DB25FD4XQ?
SPE2DB25FD4XQ was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 10, 2025.
How much is contract SPE2DB25FD4XQ worth?
The government has obligated $16,454 on SPE2DB25FD4XQ.
Is contract SPE2DB25FD4XQ an order under another contract?
Yes. SPE2DB25FD4XQ is a delivery order under SPE2DB20D9214, an indefinite delivery contract.
Was contract SPE2DB25FD4XQ competed?
The extent of competition for SPE2DB25FD4XQ was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award